Literature DB >> 25972505

The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.

Sachin Jain1, Douglas S Krakower2, Kenneth H Mayer2.   

Abstract

Although some individuals who present for antiretroviral postexposure prophylaxis (PEP) had a 1-time exposure to human immunodeficiency virus (HIV), others may be recurrently risky. Given that preexposure prophylaxis (PrEP) has been shown to be efficacious, identification of those individuals who present for PEP who might benefit from PrEP is important to decrease HIV acquisition in high-risk individuals. While inclusion criteria for PrEP have been developed, there is a paucity of data to help clinicians determine which PEP users are at highest risk for HIV acquisition and therefore should be offered PrEP. We will discuss the rationale for using PrEP after PEP use, and will focus on the assessment of PEP users who may benefit from PrEP.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV prevention; postexposure prophylaxis; preexposure prophylaxis

Mesh:

Substances:

Year:  2015        PMID: 25972505      PMCID: PMC4492410          DOI: 10.1093/cid/civ094

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston community health center: 1997-2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2015-01       Impact factor: 5.078

Review 2.  Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.

Authors:  Sachin Jain; Kenneth H Mayer
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

3.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

6.  Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors:  C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

7.  HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study.

Authors:  Douglas Krakower; Norma Ware; Jennifer A Mitty; Kevin Maloney; Kenneth H Mayer
Journal:  AIDS Behav       Date:  2014-09

8.  Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.

Authors:  Mauro Schechter; Regina F do Lago; Aaron B Mendelsohn; Ronaldo I Moreira; Lawrence H Moulton; Lee H Harrison
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-15       Impact factor: 3.731

9.  HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.

Authors:  Jeanne M Marrazzo; Carlos del Rio; David R Holtgrave; Myron S Cohen; Seth C Kalichman; Kenneth H Mayer; Julio S G Montaner; Darrell P Wheeler; Robert M Grant; Beatriz Grinsztejn; N Kumarasamy; Steven Shoptaw; Rochelle P Walensky; Francois Dabis; Jeremy Sugarman; Constance A Benson
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

10.  HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.

Authors:  Teri Liegler; Mohamed Abdel-Mohsen; L Gordon Bentley; Robert Atchison; Timothy Schmidt; Jacqueline Javier; Megha Mehrotra; Christopher Eden; David V Glidden; Vanessa McMahan; Peter L Anderson; Peilin Li; Joseph K Wong; Susan Buchbinder; Juan V Guanira; Robert M Grant
Journal:  J Infect Dis       Date:  2014-04-16       Impact factor: 5.226

View more
  8 in total

1.  Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Authors:  Kenneth H Mayer; Daniel Jones; Catherine Oldenburg; Sachin Jain; Marcy Gelman; Shayne Zaslow; Chris Grasso; Matthew J Mimiaga
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

2.  HIV Risk and Prevention Outcomes in a Probability-Based Sample of Gay and Bisexual Men in the United States.

Authors:  Brian Dodge; Jessie V Ford; Na Bo; Wanzhu Tu; John Pachankis; Debby Herbenick; Kenneth Mayer; Mark L Hatzenbuehler
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-01       Impact factor: 3.731

3.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

4.  HIV testing, care, and treatment experiences among the steady male partners of female sex workers living with HIV in the Dominican Republic.

Authors:  Paul J Fleming; Clare Barrington; Martha Perez; Yeycy Donastorg; Deanna Kerrigan
Journal:  AIDS Care       Date:  2016-03-24

5.  PrEP Continuation, HIV and STI Testing Rates, and Delivery of Preventive Care in a Clinic-Based Cohort.

Authors:  Matthew A Hevey; Jennifer L Walsh; Andrew E Petroll
Journal:  AIDS Educ Prev       Date:  2018-10

6.  Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016-June 2018.

Authors:  Nathan W Furukawa; Dawn K Smith; Charles J Gonzalez; Ya-Lin A Huang; David B Hanna; Uriel R Felsen; Weiming Zhu; Julia H Arnsten; Viraj V Patel
Journal:  Public Health Rep       Date:  2020-02-06       Impact factor: 3.117

Review 7.  Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment.

Authors:  Robert M Grant; Dawn K Smith
Journal:  Open Forum Infect Dis       Date:  2015-08-26       Impact factor: 3.835

8.  Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk.

Authors:  James Wilton; Taylor Kain; Shawn Fowler; Trevor A Hart; Troy Grennan; John Maxwell; Darrell Hs Tan
Journal:  J Int AIDS Soc       Date:  2016-06-03       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.